DXCM Share Price Performance
US$72.86
-12.82 (-14.96%)
10.8% undervalued intrinsic discount
US$81.64
Fair Value
Price US$72.86
AnalystConsensusTarget US$81.64
AnalystLowTarget US$65.00
Fair ValueUS$81.64
Share Pricen/a
DexCom, Inc. Stock Price
- 2 Narratives written by author
- 1 Comments on narratives written by author
- 145 Fair Values set on narratives written by author
DXCM Community Narratives
AN
Fair Value
·Fair Value US$81.64 10.8% undervalued intrinsic discount
DXCM: Expanding Reimbursement Will Drive Gains Despite Market Uncertainty
0users have liked this narrative
1users have commented on this narrative
69users have followed this narrative
AN
Fair Value
·Fair Value US$65 12.1% overvalued intrinsic discount
Type 2 Coverage Expansion And AI Features Will Shape A Balanced Long Term Outlook
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
DXCM: Expanding Reimbursement Will Drive Gains Despite Market Uncertainty
DexCom could get a fresh wave of customers as more insurers and countries start paying for its glucose sensors, including people with type 2 diabetes who were previously left out. But tougher pricing rules, fast-moving rivals, and hiccups in product upgrades and supply could still chip away at its edge.Read more
AN
US$81.64
10.8% undervalued intrinsic discount
Fair Value
Revenue
11.66% p.a.
Profit Margin
21.27%
Future PE
26.18x
Price in 2029
US$101.63
Type 2 Coverage Expansion And AI Features Will Shape A Balanced Long Term Outlook
Catalysts About DexCom DexCom develops and sells continuous glucose monitoring systems used by people with diabetes around the world. What are the underlying business or industry changes driving this perspective?Read more
AN
US$65
12.1% overvalued intrinsic discount
Fair Value
Revenue
9.79% p.a.
Profit Margin
21.8%
Future PE
21.61x
Price in 2029
US$81.64
Trending Discussion
Recently Updated Narratives
AN
DXCM: New Long Term Framework And Buybacks Will Support Future Momentum
Fair Value: US$81.64 10.8% undervalued intrinsic discount
69 fair values setusers have set this as their fair value
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
Type 2 Coverage Expansion And AI Features Will Shape A Balanced Long Term Outlook
Fair Value: US$65 12.1% overvalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
DexCom, Inc. Key Details
About DXCM
- Founded
- 1999
- Employees
- 11050
- CEO
- WebsiteView website
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
